Healx vs Niramai

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Healx employs 1-50 people, while Niramai has 50-200 employees.

Healx has raised more in total funding at $47M, compared to Niramai's $17M — a gap of $30M.

Niramai holds the higher Awaira Score at 60/100, compared to Healx's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Healx was founded by Tim Guilliams in 2014. Niramai was founded by Geetha Manjunath in 2016. Visit each company's profile on Awaira for a full founder biography.

Healx: Healx uses AI to identify and develop treatments for rare diseases, applying graph neural networks and multi-omics data analysis to repurpose existing approved drugs for new orphan disease indications. The Cambridge-based company focuses exclusively on rare diseases, where the small patient populations and limited existing literature make traditional drug discovery economically unviable without computational approaches that can extract signal from sparse data.\n\nThe company raised a $47 million Series B led by Balderton Capital and includes strategic investors from the rare disease patient advocacy community. Healx has assembled a pipeline of repurposing candidates for conditions including Fragile X syndrome, tuberous sclerosis complex, and other rare neurodevelopmental disorders, with several candidates advancing into clinical studies. The company partners with patient advocacy groups to access natural history data and patient registries that inform its disease models.\n\nHealx operates in a rare disease AI market that is less crowded than oncology-focused drug discovery AI but equally challenging due to regulatory complexity and small trial populations. The company competes with Healios, BenevolentAI, and specialist rare disease biotechs that are increasingly adopting computational methods. Its exclusive focus on rare diseases and its community partnerships represent a defensible niche that larger generalist AI drug discovery platforms have not prioritised. Niramai: Niramai has developed a radiation-free, non-contact breast cancer screening solution that uses thermal imaging combined with AI-powered image analysis to detect early-stage breast cancer, addressing the significant access and cost barriers that prevent widespread mammography screening in low- and middle-income countries. The technology works without X-ray radiation, requires no radiologist for initial interpretation, and can be deployed in mobile screening units.\n\nThe company raised approximately $17M in Series B funding and has conducted clinical validation studies demonstrating sensitivity and specificity metrics competitive with mammography for early detection. Niramai has deployed its screening solution at hospitals, corporate wellness programs, and rural health camps across India.\n\nBreast cancer is the most common cancer among Indian women, yet screening rates remain critically low due to equipment costs, specialist shortages, and cultural barriers to mammography. Niramai's AI-powered thermal screening addresses each of these barriers simultaneously, positioning the company at the intersection of AI healthcare innovation and a major Indian public health challenge.

Healx was founded first in 2014, giving it 2 years of additional market experience. Niramai was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Healx has approximately 1-50 employees, while Niramai has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Healx and Niramai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.